摘要
Objective:To evaluate the tumor load and adverse reactions of nedaplatin combined with paclitaxel liposome and with paclitaxel treatment of advanced esophageal cancer.Methods:A total of 68 patients with advanced esophageal cancer who were treated in our hospital between August 2013 and March 2016 were collected and divided into the paclitaxel liposome group (n=34) who received nedaplatin combined with paclitaxel liposome therapy and the paclitaxel group (n=34) who received nedaplatin combined with paclitaxel therapy according to the double-blind randomized control method, and both therapies lasted for 8 weeks. Before treatment and after 8 weeks of treatment, RIA method was used to determine serum esophageal cancer-related tumor marker levels, enzyme-linked immunosorbent assay was used to determine serum angiogenesis index levels, and flow cytometry was used to measure cellular immunity indexes.Results: Before treatment, the differences in serum tumor marker and angiogenesis index levels as well as cellular immune function indexes were not statistically significant between the two groups. After 8 weeks of treatment, serum tumor markers CY211, CEA, SCC, CA724 and CA125 levels of observation group were lower than those of control group, angiogenesis indexes HIF-α, VEGF and MMP-9 levels were lower than those of control group, and peripheral blood cellular immunity indexes CD4+ and CD4+/CD8+ levels were higher than those of control group while CD8+ level was lower than that of control group. Conclusion: Nedaplatin combined with paclitaxel liposome can more effectively reduce the tumor load, causes less adverse effects, and has good curative effect and security.
